KRAS and cancer: Pancreatic cancer cells harbor several gene mutations during the course of cancer development, with Kirsten rat sarcoma (KRAS) mutations accounting for 94.1%, followed by TP53 (63.9%), SMAD4 (20.8%), and CDKN2A mutations (17.0%) [8].